

Kawartha Centre is currently enrolling for the following clinical trials. The investigational drugs under study are not available through standard care. If you are interested in learning more, please contact research@kawarthacentre.com or by phone at 705-749-3906 x209.

Sponsor and Protocol	Phase	Indication	Age	MMSE	Drug / mechanism of Action	Category
COMPASS-ND http://ccna-ccnv.ca/en/compass-nd-study/	--	MCI, mixed dementia, Mild AD, vascular	60 - 85		N/A	Longitudinal observational study
Eisai E2609-G000-301 (MISSION AD) https://clinicaltrials.gov/ct2/show/NCT02956486	III	Early Alzheimer's Disease (EAD) including MCI due to AD and mild AD	50 – 85	24 – 30	elenbecestat (BACE 1 inhibitor)	Disease modifying
Eli Lilly IST-MC-AACG (TRAILBLAZER) https://clinicaltrials.gov/ct2/show/study/NCT03367403	II	Early Symptomatic AD	60 - 85	N/A	LY3002813 (anti A-beta) alone or in combination with LY3202626 (BACE 1 inhibitor)	Disease modifying
Regenera Pharma RGN-ADC-002 https://clinicaltrials.gov/ct2/show/NCT03462121	II	Mild to moderate AD (with or without coexisting cerebrovascular disease)	65 or older	15 -22	RPh201 purified plant extract	